Non-coding RNAs: new biomarkers and therapeutic targets for esophageal cancer

Xiaobin Hou, Jiaxin Wen, Zhipeng Ren and Guoliang Zhang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:43571-43578. https://doi.org/10.18632/oncotarget.16721

Metrics: PDF 4304 views  |   HTML 3779 views  |   ?  


Xiaobin Hou1,*, Jiaxin Wen1,*, Zhipeng Ren1 and Guoliang Zhang2

1 Department of Thoracic Surgery, PLA General Hospital, Beijing, China

2 Medical Science Weekly, Beijing, China

* These authors have contributed to this work equally

Correspondence to:

Guoliang Zhang, email:

Keywords: esophageal cancer; lncRNAs; miRNAs; biomarker; therapeutic target

Received: November 11, 2016 Accepted: January 27, 2017 Published: March 30, 2017


Esophageal cancer is one of the most common gastrointestinal malignant diseases and there is still no effective treatment. The incidence of esophageal cancer in the world is relatively high and on the increase year by year. Thus, the elaboration on the carcinogenesis of esophageal cancer and the identification of new biomarkers and therapeutic targets is quite beneficial to optimizing the current therapeutic regimen for treating such deadly disease. More and more evidence has shown that non-coding RNAs play an important role in the development and progression of multiple human cancers, including esophageal cancer. microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are two functional kinds of non-coding RNAs that have been well investigated. They exert tumor suppressive or promoting effect by specifically regulating the expression of certain downstream target genes, which is tumor specific. It is also proved that miRNAs and lncRNAs level in tissue and plasma from esophageal cancer patients are closely correlated with the survival and disease progression, which could be used as a prognostic factor and therapeutic target for esophageal cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16721